Ultrasound Diagnosis of Giant Testicular Adrenal Residual Tumors: A Case Report and Literature Review.

J Clin UltrasoundApr 21, 2026 (epub)
Case ReportPediatricsEndocrinologyOpen access

Yanyan Ge, Hongjing Zhu, Dejuan Kong et al.

✦ AI-curated · Sources linked

Case in brief

A 9-year-old male with congenital adrenal hyperplasia presented with giant testicular adrenal residual tumors (TARTs) associated with 11β-hydroxylase deficiency. Ultrasound imaging facilitated the diagnosis, and the clinical course indicated that early intervention could effectively reduce tumor size and potentially reverse early testicular function damage.

What made this case unusual

This case highlights the rare occurrence of TARTs in the context of 11β-hydroxylase deficiency, contrasting with the more commonly reported 21-hydroxylase deficiency.

Diagnostic / clinical pearl

Ultrasound is crucial for the early diagnosis and monitoring of testicular adrenal residual tumors in pediatric patients.

Why it matters

Recognizing the potential for reversibility in testicular function with timely intervention underscores the importance of early diagnosis in managing TARTs.

Source

Published in J Clin Ultrasound. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.